Evaluating Prior Lenalidomide or Proteasome Inhibitor Exposure on Treatment Effectiveness in Patients in the INSURE study

Associate Professor Karthik Ramasamy

Prescribing information is available at the top of the page.

Listen to Associate Professor Karthik Ramasamy discuss the real-world evidence from the INSURE study, exploring whether some patients could benefit from retreatment with LEN or proteasome inhibitors during their treatment of RRMM.^1,2

Associate Professor Ramasamy also presents a case study of a patient with relapsed MM.

If you would like to discuss this content with a Takeda representative, please click here.

NINLARO® (ixazomib) in combination with lenalidomide and dexamethasone is indicated for the treatment of adult patients with multiple myeloma who have received at least one prior therapy.³

LEN, lenalidomide; MM, multiple myeloma; NRd, NINLARO + lenalidomide + dexamethasone; RRMM, relapsed/refractory multiple myeloma.
1. Lee HC, et al. Eur J Haematol 2024;113:190-200; 2. Leleu X, et al. Future Oncol 2024;20:935–950; 3. NINLARO. Summary of Product Characteristics (Great Britain).

To enjoy the full experience of OncoConnect, including the ability to like and bookmark content for easy access via your account section, please register or login now.

Related content

Prescribing information Ninlaro

Real-world evidence: Treating patients with RRMM with prior lenalidomide exposure

The INSURE study is a pooled, global analysis of three observational studies (INSIGHT MM, UVEA-IXA and REMIX).¹ Results from this study demonstrated minimal impact of prior lenalidomide exposure on the effectiveness of NINLARO^®(ixazomib) with lenalidomide and dexamethasone (NRd) in lenalidomide-non-refractory adult patients with RRMM treated in routine clinical practice.¹ It was concluded that prior lenalidomide exposure (but not refractoriness) should not preclude the use of NRd in later lines of treatment in patients with RRMM, and no new safety concerns were reported for NRd.¹

Prescribing information Ninlaro

How can we determine whether lenalidomide rechallenge is an option for patients with RRMM?

Lenalidomide has become an integral part of first-line treatment in patients with multiple myeloma.¹ As patients progress to later lines, options can become limited, and the choice of treatment offered in patients who relapse should be carefully evaluated.² Defining and understanding the lenalidomide status of patients with multiple myeloma can help guide the next line of treatment and which patients can be rechallenged appropriately with lenalidomide post relapse.